Eagle Pharmaceuticals (EGRX) Posts Q4 Loss of 65c/Share

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of ($0.65), $0.16 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $2.81 million versus the consensus estimate of $2.73 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Obsidian Energy Increases Syndicated Credit Facility